J Korean Breast Cancer Soc.
2003 Sep;6(3):196-200. 10.4048/jkbcs.2003.6.3.196.
Two Cases of Endometrial Carcinoma in Tamoxifen-treated Breast Cancer Patients in Korea
- Affiliations
-
- 1Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea. wcpark@catholic.ac.kr
- KMID: 2006636
- DOI: http://doi.org/10.4048/jkbcs.2003.6.3.196
Abstract
- Tamoxifen, the representative of selective estrogen receptor modulaor (SERM), has been widely used not only for the treatment of breast cancer, but also for the prevention of the disease. It is well known that some serious side-effects can infrequently occur with long-term use of tamoxifen and endometrial cancer is one of that disasters. According to NSABP B-14 data, the incidence of endometrial cancer among tamoxifen users was 0.16% and the relative risk was increased by 7.2 fold. In Korea, tamoxifen has been also used as primary endocrine therapy for the treatment of many patients with breast cancer. However, there was no formal report about the endometrial carcinoma occurred subsequently after tamoxifen administration so far. Recently, we experienced two cases of endometrial carcinoma occurred after tamoxifen treatment in breast cancer patients in Korea, and report these cases for reminding breast physicians or patients not to ignore this rare, but serious side effect of tamoxifen.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Cases with Endometrial Polyp and Endocervical Polyp Associated With Tamoxifen Use
- The Change of Endometrial Thickness in Tamoxifen-treated Postmenopausal Breast Cancer Patients
- A case of carcinosarcoma of uterine endometrium associated with Tamoxifen use in breast cancer patient
- Relationship between long-term use of tamoxifen and endometrial cancer in patients with breast cancer
- Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen
